SYBX (Synlogic) רווח למניה בארבעת הרבעונים האחרונים

Synlogic, Inc. (SYBX) is monetizing an innovative synthetic biotic system, establishing a foundation for licensing payments. However, historical YoY EPS growth over the last 12 months shows a sharp decline: the macro-resilience of therapies for congenital metabolic pathologies did not save the asset from restructuring and liquidation. The business is currently burdened by costs associated with settling obligations, and the indicator value reaches 93.60.

Year-over-year EPS growth (TTM) measures the net profit per share dynamics over twelve months, allowing for an assessment of value generation efficiency relative to the previous period. By analyzing the history of year-over-year EPS (TTM) changes, an investor can see the impact of laboratory robotization at Synlogic, Inc. (SYBX) on profitability, where the automation of dosing and data validation should translate into cost reductions and an increase in per-unit income.